Azitra Inc
As of Oct 22, 2026, Azitra is in Stage 4, the downtrend phase, now in its first week (since Oct 16, 2026). It closed at $0.07, 87.8% below its 52-week high and below its 200-day average, which is falling.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is AZTR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AZTR among Biotechnology508th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …508 | AZTR | Stage 4 · wk 1 | 7 | −57.9% |
Azitra: quick answers
What stage is Azitra in?
As of Oct 22, 2026, Azitra (AZTR) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 16, 2026 and is in its first week there. What the four stages mean
Is Azitra in an uptrend?
No. Azitra is in a Stage 4 downtrend. It trades 62.1% below its 200-day average, which is falling.
How far is Azitra from its 52-week high?
Azitra closed at $0.07 on Oct 22, 2026, 87.8% below its 52-week high of $0.59. Its 52-week low is $0.07.
How has Azitra performed over the past year?
As of Oct 22, 2026, Azitra is down 89.6% over the past year and down 72.8% so far in 2026.
Which sector and industry is Azitra in?
Azitra is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.